Type 2 diabetes mellitus. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Will receive 10 g/day of Purslane seed powder with 240cc low fat yogurt for 5 weeks. Intervention 2: Control group: Will receive 240cc/day low fat yogurt for 5 wee
Treatment - Other
Intervention group: Will receive 10 g/day of Purslane seed powder with 240cc low fat yogurt for 5 weeks
Control group: Will receive 240cc/day low fat yogurt for 5 weeks
Sponsors
Vice chancellor for research, Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Non- Insulin dependent type 2 diabetic Patients; Non-smokers and lack of alcohol use; Not consuming supplements two weeks before the study and during the study; Non-pregnant and non-lactating women; Aged 35-65 years; No Change in dosage and type of medications at least two months prior to study; No history of hepatic, renal, lung, cardiovascular, kidney stone, thyroid diseases and gastro-intestinal bleeding; No history of myocardial infarction and stroke; Not affected by Severe non-proliferative or proliferative retinopathy; Not affected by malignant hypertension. Exclusion criteria: Change in diet or physical activity patterns during the study; injection of Insulin during study; Changes in dosage and type of medications throughout the study; Unwillingness to continue.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Malondialdehyde level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Commercial kits.;Serum oxidized LDL level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Commercial kits.;Total antioxidant capacity level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Commercial kits. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum Insulin level. Timepoint: At baseline and after each phase of intervention. Method of measurement: IRMA.;HOMA-IR. Timepoint: At baseline and after each phase of intervention. Method of measurement: Formula.;Serum triglyceride level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Enzymatic method.;Serum total cholesterol level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Enzymatic method.;Serum LDL level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Friedewald formula.;Serum HDL level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Enzymatic method.;Serum Apo A level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Immunoturbidimetry.;Serum Apo B level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Immunoturbidimetry.;Fasting Plasma glucose level. Timepoint: At baseline and after each phase of intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: At baseline and after each phase of intervention. Method of measurement: Scale.;Waist circumference. Timepoint: At baseline and after each phase of intervention. Method of measurement: Un stretched measure.;Systolic blood pressure. Timepoint: At baseline and after each phase of intervention. Method of measurement: Mercurial sphygmomanometer.;Diastolic blood pressure. Timepoint: At baseline and after each phase of intervention. Method of measurement: Mercurial sphygmomanometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElahe Zakizadeh
Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medic
Outcome results
None listed